Treatment of symptomatic coronary artery disease in patients with end-stage renal disease on hemodialysis with paclitaxel-eluting TAXUS stent

Percutaneous coronary intervention (PCI) utilizing drug‐eluting stents is becoming a very common revascularization technique in the dialysis cohort; therefore, we sought to identify the impact of dialysis on outcomes in this group of patients. This is a multicenter registry comparing results of 290...

Full description

Saved in:
Bibliographic Details
Published in:Hemodialysis international 2015-07, Vol.19 (3), p.402-411
Main Authors: Wiernek, Szymon L., Kiesz, R. Stefan, Wiernek, Barbara K., Buszman, Piotr P., Janas, Adam, Martin, Jack L., Trela, Blazej, Szewc, Robert G., Buszman, Pawel E.
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - therapeutic use
Coronary Artery Disease - surgery
dialysis
drug-eluting stents
Drug-Eluting Stents - statistics & numerical data
End-stage renal disease
Female
Humans
Kidney Failure, Chronic - drug therapy
Kidney Failure, Chronic - surgery
Male
Middle Aged
paclitaxel
Paclitaxel - administration & dosage
Paclitaxel - therapeutic use
percutaneous coronary intervention
Percutaneous Coronary Intervention - methods
Prospective Studies
Renal Dialysis - methods
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Percutaneous coronary intervention (PCI) utilizing drug‐eluting stents is becoming a very common revascularization technique in the dialysis cohort; therefore, we sought to identify the impact of dialysis on outcomes in this group of patients. This is a multicenter registry comparing results of 290 patients (186 with normal kidney function, 104 on dialysis) who underwent PCI with exclusive use of paclitaxel‐eluting TAXUS stent. The primary endpoint was an assessment of major adverse cardiac events (MACE) at 1‐ and 2‐year observation. Mean follow‐up was 23.3 ± 6.1 months. Results at 12 months showed: MACE 11.8% vs. 7.7% (P = not significant [ns]), composite major adverse cardiac and cerebrovascular events (MACCE) 12.4% vs. 11.5% (P = ns), all‐cause death 2.7% vs. 8.6% (P 
ISSN:1492-7535
1542-4758
DOI:10.1111/hdi.12259